WSO - March 2024 - 358

358
International Journal of Stroke 19(3)
study of 8,751 UK Biobank participants. J Comorb 2018; 8:
1-8.
13. Goldstein LB, Samsa GP, Matchar DB and Horner RD.
Charlson Index comorbidity adjustment for ischemic stroke
outcome studies. Stroke 2004; 35: 1941-1945.
14. Zhu H and Hill MD. Stroke: the Elixhauser Index for comorbidity
adjustment of in-hospital case fatality. Neurology 2008;
71: 283-287.
15. A classification and outline of cerebrovascular diseases. II.
Stroke 1975; 6: 564-616.
16. Coull AJ, Silver LE, Bull LM, Giles MF and Rothwell PM;
Oxford Vascular (OXVASC) Study. Direct assessment of
completeness of ascertainment in a stroke incidence study.
Stroke 2004; 35: 2041-2045.
17. Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke
incidence, mortality, case-fatality, severity, and risk factors in
Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study).
Lancet 2004; 363: 1925-1933.
18. Rothwell PM, Coull AJ, Silver LE, et al. Population-based
study of event-rate, incidence, case fatality, and mortality
for all acute vascular events in all arterial territories (Oxford
Vascular Study). Lancet 2005; 366: 1773-1783.
19. Lyden P. Using the National Institutes of Health Stroke Scale.
Stroke 2017; 48: 513-519.
20. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ and
Van Gijn J. Interobserver agreement for the assessment of
handicap in stroke patients. Stroke 1988; 19: 604-607.
21. Abel GA, Barclay ME and Payne RA. Adjusted indices
of multiple deprivation to enable comparisons within and
between constituent countries of the UK including an illustration
using mortality rates. BMJ Open 2016; 6: e012750.
22. Adams HP, Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB,
Gordon DL and Marsh EE. Classification of subtype of acute
ischemic stroke. Definitions for use in a multicenter clinical
trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
Stroke 1993; 24: 35-41.
23. Flint AC, Cullen SP, Faigeles BS and Rao VA. Predicting longterm
outcome after endovascular stroke treatment: the totaled
health risks in vascular events score. AJNR Am J Neuroradiol
2010; 31: 1192-1196.
24. Drozdowska BA, Singh S and Quinn TJ. Thinking about the
future: a review of prognostic scales used in acute stroke.
Front Neurol 2019; 10: 274.
25. Espinoza SE, Quiben M and Hazuda HP. Distinguishing
comorbidity, disability, and frailty. Curr Geriatr Rep 2018; 7:
201-209.
26. Evans NR, Todd OM, Minhas JS, et al. Frailty and cerebrovascular
disease: concepts and clinical implications for stroke
medicine. Int J Stroke 2022; 17: 251-259.
27. Marengoni A, Von Strauss E, Rizzuto D, Winblad B and
Fratiglioni L. The impact of chronic multimorbidity and disability
on functional decline and survival in elderly persons.
A community-based, longitudinal study. J Intern Med 2009;
265: 288-295.
28. Nunes BP, Flores TR, Mielke GI, Thumé E and Facchini LA.
Multimorbidity and mortality in older adults: a systematic review
and meta-analysis. Arch Gerontol Geriatr 2016; 67: 130-138.
29. Williams JS and Egede LE. The association between multimorbidity
and quality of life, health status and functional disability.
Am J Med Sci 2016; 352: 45-52.
30. Jiménez Caballero PE, López Espuela F, Portilla Cuenca
JC, Ramírez Moreno JM, Pedrera Zamorano JD and Casado
Naranjo I. Charlson comorbidity index in ischemic stroke
and intracerebral hemorrhage as predictor of mortality and
functional outcome after 6 months. J Stroke Cerebrovasc Dis
2013; 22: e214-e218.
31. Teale EA, Forster A, Munyombwe T and Young JB. A systematic
review of case-mix adjustment models for stroke. Clin
Rehabil 2012; 26: 771-786.
32. Smith SM, Wallace E, O'Dowd T and Fortin M. Interventions
for improving outcomes in patients with multimorbidity in
primary care and community settings. Cochrane Database
Syst Rev 2021; 1: CD006560.
33. Quinn TJ, Taylor-Rowan M, Coyte A, et al. Pre-stroke modified
Rankin Scale: evaluation of validity, prognostic accuracy,
and association with treatment. Front Neurol 2017; 8: 275.
34. Downer MB, Li L, Carter S, Beebe S and Rothwell PM.
Associations of multimorbidity with stroke severity, subtype,
premorbid disability, and early mortality: Oxford Vascular
Study. Neurology 2023; 101: e645-e652.
International Journal of Stroke, 19(3)

WSO - March 2024

Table of Contents for the Digital Edition of WSO - March 2024

Contents
WSO - March 2024 - Cover1
WSO - March 2024 - Cover2
WSO - March 2024 - 245
WSO - March 2024 - Contents
WSO - March 2024 - 247
WSO - March 2024 - 248
WSO - March 2024 - 249
WSO - March 2024 - 250
WSO - March 2024 - 251
WSO - March 2024 - 252
WSO - March 2024 - 253
WSO - March 2024 - 254
WSO - March 2024 - 255
WSO - March 2024 - 256
WSO - March 2024 - 257
WSO - March 2024 - 258
WSO - March 2024 - 259
WSO - March 2024 - 260
WSO - March 2024 - 261
WSO - March 2024 - 262
WSO - March 2024 - 263
WSO - March 2024 - 264
WSO - March 2024 - 265
WSO - March 2024 - 266
WSO - March 2024 - 267
WSO - March 2024 - 268
WSO - March 2024 - 269
WSO - March 2024 - 270
WSO - March 2024 - 271
WSO - March 2024 - 272
WSO - March 2024 - 273
WSO - March 2024 - 274
WSO - March 2024 - 275
WSO - March 2024 - 276
WSO - March 2024 - 277
WSO - March 2024 - 278
WSO - March 2024 - 279
WSO - March 2024 - 280
WSO - March 2024 - 281
WSO - March 2024 - 282
WSO - March 2024 - 283
WSO - March 2024 - 284
WSO - March 2024 - 285
WSO - March 2024 - 286
WSO - March 2024 - 287
WSO - March 2024 - 288
WSO - March 2024 - 289
WSO - March 2024 - 290
WSO - March 2024 - 291
WSO - March 2024 - 292
WSO - March 2024 - 293
WSO - March 2024 - 294
WSO - March 2024 - 295
WSO - March 2024 - 296
WSO - March 2024 - 297
WSO - March 2024 - 298
WSO - March 2024 - 299
WSO - March 2024 - 300
WSO - March 2024 - 301
WSO - March 2024 - 302
WSO - March 2024 - 303
WSO - March 2024 - 304
WSO - March 2024 - 305
WSO - March 2024 - 306
WSO - March 2024 - 307
WSO - March 2024 - 308
WSO - March 2024 - 309
WSO - March 2024 - 310
WSO - March 2024 - 311
WSO - March 2024 - 312
WSO - March 2024 - 313
WSO - March 2024 - 314
WSO - March 2024 - 315
WSO - March 2024 - 316
WSO - March 2024 - 317
WSO - March 2024 - 318
WSO - March 2024 - 319
WSO - March 2024 - 320
WSO - March 2024 - 321
WSO - March 2024 - 322
WSO - March 2024 - 323
WSO - March 2024 - 324
WSO - March 2024 - 325
WSO - March 2024 - 326
WSO - March 2024 - 327
WSO - March 2024 - 328
WSO - March 2024 - 329
WSO - March 2024 - 330
WSO - March 2024 - 331
WSO - March 2024 - 332
WSO - March 2024 - 333
WSO - March 2024 - 334
WSO - March 2024 - 335
WSO - March 2024 - 336
WSO - March 2024 - 337
WSO - March 2024 - 338
WSO - March 2024 - 339
WSO - March 2024 - 340
WSO - March 2024 - 341
WSO - March 2024 - 342
WSO - March 2024 - 343
WSO - March 2024 - 344
WSO - March 2024 - 345
WSO - March 2024 - 346
WSO - March 2024 - 347
WSO - March 2024 - 348
WSO - March 2024 - 349
WSO - March 2024 - 350
WSO - March 2024 - 351
WSO - March 2024 - 352
WSO - March 2024 - 353
WSO - March 2024 - 354
WSO - March 2024 - 355
WSO - March 2024 - 356
WSO - March 2024 - 357
WSO - March 2024 - 358
WSO - March 2024 - 359
WSO - March 2024 - 360
WSO - March 2024 - 361
WSO - March 2024 - 362
WSO - March 2024 - 363
WSO - March 2024 - 364
WSO - March 2024 - 365
WSO - March 2024 - 366
WSO - March 2024 - 367
WSO - March 2024 - 368
WSO - March 2024 - 369
WSO - March 2024 - 370
WSO - March 2024 - 371
WSO - March 2024 - 372
WSO - March 2024 - Cover3
WSO - March 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com